Phase 1 Open-label Study of the Absorption, Metabolism, and Excretion of Poziotinib Following a Single Oral Dose of [14C]-Poziotinib in Healthy Male Subjects
Latest Information Update: 02 Nov 2021
Price :
$35 *
At a glance
- Drugs Poziotinib (Primary)
- Indications Breast cancer; Colorectal cancer; Gastric cancer; Glioma; Head and neck cancer; Lung cancer; Non-small cell lung cancer; Solid tumours
- Focus Pharmacokinetics
- Sponsors Spectrum Pharmaceuticals
- 17 Sep 2021 Results assessing the mass balance, excretion, pharmacokinetics (PK) and safety of poziotinib in healthy male subjects, presented at the 2021 American College of Clinical Pharmacology Annual Meeting.
- 14 Jan 2021 Status changed from recruiting to completed.
- 24 Jun 2020 New trial record